Web3 GenPharmaChain Incubated by M2M Capital

GenPharmaChain, an innovative web3 Desci project focused on integrating AI, protein research, and disease databases to advance drug development, has officially announced its incubation by renowned investment firm M2M Capital. The specific funding amount for this incubation plan has not been disclosed.GenPharmaChain leverages artificial intelligence and blockchain technology to streamline the entire pharmaceutical industry. The company has developed an AI-assisted research platform that helps researchers discover and develop drugs more efficiently. Users can train AI models on the platform, participate in the pharmaceutical process, and even invest in pharmaceutical factories and drugs under development. Through collaborations with pharmaceutical factories in India and Bangladesh, GenPharmaChain is actively promoting the development of the Web3 pharmaceutical ecosystem.

Additionally, GenPharmaChain actively participates in various academic forums, sharing its research findings in the decentralized science (DeSci) field. The company aims to accelerate the drug development process and enhance the transparency and security of the pharmaceutical supply chain through transparent and efficient data management.

About M2M Capital M2M Capital is a venture capital firm specializing in investing in and incubating emerging technology companies, with a wealth of industry experience and a successful track record. The firm is committed to supporting innovative companies from the concept stage to becoming market leaders by providing funds and resources. M2M Capital has previously invested in several successful projects, including the Gamefi Project Panda Titan and NexGen.

Through this incubation, M2M Capital will provide comprehensive support to GenPharmaChain, including funds, resources, and industry expertise, to further its development in the blockchain and AI pharmaceutical sectors.

Twitter：https://x.com/Genpharmchain